Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
04/15/2021 04/16/2021 04/19/2021 04/20/2021 04/21/2021 Date
7196 7243 7339 7345 7216 Last
548400 491200 643700 738400 854000 Volume
-0.06% +0.65% +1.33% +0.08% -1.76% Change
Financials
Sales 2021 659 B 6 094 M 6 094 M
Net income 2021 46 073 M 426 M 426 M
Net cash position 2021 163 B 1 504 M 1 504 M
P/E ratio 2021 44,7x
Yield 2021 2,18%
Sales 2022 707 B 6 532 M 6 532 M
Net income 2022 66 513 M 615 M 615 M
Net cash position 2022 178 B 1 642 M 1 642 M
P/E ratio 2022 32,0x
Yield 2022 2,25%
Capitalization 2 106 B 19 473 M 19 461 M
EV / Sales 2021 2,95x
EV / Sales 2022 2,73x
Nbr of Employees 10 998
Free-Float 87,5%
More Financials
Company
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (87.7%): prescribed drugs, health products, etc.; - other (12.3%): food additives, chemical products, etc. Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%). 
Sector
Pharmaceuticals
Calendar
04/20 | 05:00amPresentation
More about the company
Notations Surperformance© of Eisai Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about EISAI CO., LTD.
02:01aBIOARCTIC  : Interim Report for the period January - March 2021
AQ
04/20BIOARCTIC  : Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease pub..
AQ
04/19EISAI : 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinica..
AQ
04/14EISAI  : to Present Latest Data on Neurology Products and Pipelines at the Ameri..
AQ
04/12EISAI : Animation Featuring Lymphatic Filariasis Elimination Activities Receives..
AQ
04/01EISAI  : And advocacy leaders team up to launch spot her - an initiative that em..
AQ
04/01EISAI  : Application submitted for additional indication of anti cancer agent le..
AQ
03/31EISAI  : KYORIN and Eisai Enter Into License Agreement Concerning the Developmen..
AQ
03/31EISAI : Application Submitted for Additional Indication of Anti Cancer Agent Len..
AQ
03/30EISAI  : European medicines agency accepts the marketing authorisation applicati..
AQ
03/30EISAI : European Medicines Agency Accepts the Marketing Authorisation Applicatio..
AQ
03/30EISAI CO., LTD. : Ex-dividend day for final dividend
FA
03/26EISAI  : Discovery research on ampa-type glutamate receptor antagonist perampane..
AQ
03/25EISAI : Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel..
AQ
03/24EISAI  : ANTICANCER AGENT Remitoro INTRAVENOUS DRIP INFUSION 300g APPROVED IN JA..
AQ
More news
News in other languages on EISAI CO., LTD.
01/12TOKYO STOCK EXCHANGE : Borsa Tokyo, nuovo massimo da 30 anni, farmaceutici in ra..
01/11EISAI  : Medicamento de Eli Lilly para el alzhéimer retrasa declive mental y fun..
2020TOKYO STOCK EXCHANGE : Borsa Tokyo chiude a massimo 29 anni su rimbalzo Pil, pro..
2020Les Bourses mondiales savourent la victoire de Biden
2020TOKYO STOCK EXCHANGE : Borsa Tokyo chiude a massimi di circa 30 anni su Biden vi..
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Stock Trading Strategies
EISAI CO., LTD. - 2020
The calm spell can be taken advantage of to put on new positions
BUY
More Stock Trading Analysis
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 8 737,50 JPY
Last Close Price 7 345,00 JPY
Spread / Highest target 104%
Spread / Average Target 19,0%
Spread / Lowest Target -42,8%
EPS Revisions
Managers and Directors
NameTitle
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Lynn D. Kramer Chief Medical & Chief Clinical Officer-Neurology
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD.-0.37%19 473
JOHNSON & JOHNSON5.78%438 293
ROCHE HOLDING AG0.42%290 135
PFIZER, INC.5.76%217 716
MERCK & CO., INC.-3.95%198 884
NOVARTIS AG-3.24%198 172